EVO Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of -26.29% compared to Evotec SE's net margin of -1.89%. Evotec SE's return on equity of -17.7% beat BioNTech SE's return on equity of -3.01%.

Evotec SE has a consensus price target of $5.4436, signalling upside risk potential of 69.18%. On the other hand BioNTech SE has an analysts' consensus of $137.68 which suggests that it could grow by 43.41%. Given that Evotec SE has higher upside potential than BioNTech SE, analysts believe Evotec SE is more attractive than BioNTech SE.

Evotec SE has a beta of 1.821, which suggesting that the stock is 82.079% more volatile than S&P 500. In comparison BioNTech SE has a beta of 1.295, suggesting its more volatile than the S&P 500 by 29.477%.

Evotec SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evotec SE pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.

Evotec SE quarterly revenues are $191.5M, which are smaller than BioNTech SE quarterly revenues of $1.8B. Evotec SE's net income of -$50.3M is lower than BioNTech SE's net income of -$33.5M. Notably, Evotec SE's price-to-earnings ratio is -- while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evotec SE is 1.38x versus 6.53x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

CureVac NV has a net margin of -26.29% compared to Evotec SE's net margin of -5832.47%. Evotec SE's return on equity of -17.7% beat CureVac NV's return on equity of 20.55%.

Evotec SE has a consensus price target of $5.4436, signalling upside risk potential of 69.18%. On the other hand CureVac NV has an analysts' consensus of $5.31 which suggests that it could grow by 3.97%. Given that Evotec SE has higher upside potential than CureVac NV, analysts believe Evotec SE is more attractive than CureVac NV.

Evotec SE has a beta of 1.821, which suggesting that the stock is 82.079% more volatile than S&P 500. In comparison CureVac NV has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.063%.

Evotec SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evotec SE pays -- of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend.

Evotec SE quarterly revenues are $191.5M, which are larger than CureVac NV quarterly revenues of $63.3M. Evotec SE's net income of -$50.3M is lower than CureVac NV's net income of $319.3M. Notably, Evotec SE's price-to-earnings ratio is -- while CureVac NV's PE ratio is 7.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evotec SE is 1.38x versus 14.22x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.

InflaRx NV has a net margin of -26.29% compared to Evotec SE's net margin of -51538.49%. Evotec SE's return on equity of -17.7% beat InflaRx NV's return on equity of -82.01%.

Evotec SE has a consensus price target of $5.4436, signalling upside risk potential of 69.18%. On the other hand InflaRx NV has an analysts' consensus of $11.64 which suggests that it could grow by 1041.22%. Given that InflaRx NV has higher upside potential than Evotec SE, analysts believe InflaRx NV is more attractive than Evotec SE.

Evotec SE has a beta of 1.821, which suggesting that the stock is 82.079% more volatile than S&P 500. In comparison InflaRx NV has a beta of 1.459, suggesting its more volatile than the S&P 500 by 45.896%.

Evotec SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evotec SE pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.

Evotec SE quarterly revenues are $191.5M, which are larger than InflaRx NV quarterly revenues of $27.8K. Evotec SE's net income of -$50.3M is lower than InflaRx NV's net income of -$14.3M. Notably, Evotec SE's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evotec SE is 1.38x versus 315.16x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.

Immatics NV has a net margin of -26.29% compared to Evotec SE's net margin of -974.45%. Evotec SE's return on equity of -17.7% beat Immatics NV's return on equity of -25.21%.

Evotec SE has a consensus price target of $5.4436, signalling upside risk potential of 69.18%. On the other hand Immatics NV has an analysts' consensus of $18.63 which suggests that it could grow by 80.13%. Given that Immatics NV has higher upside potential than Evotec SE, analysts believe Immatics NV is more attractive than Evotec SE.

Evotec SE has a beta of 1.821, which suggesting that the stock is 82.079% more volatile than S&P 500. In comparison Immatics NV has a beta of 1.361, suggesting its more volatile than the S&P 500 by 36.134%.

Evotec SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evotec SE pays -- of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.

Evotec SE quarterly revenues are $191.5M, which are larger than Immatics NV quarterly revenues of $6.1M. Evotec SE's net income of -$50.3M is higher than Immatics NV's net income of -$59.1M. Notably, Evotec SE's price-to-earnings ratio is -- while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evotec SE is 1.38x versus 13.81x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.